Marcela V. Maus, M.D.,Ph.D. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   Emapalumab Prevention of CAR-T Cell Associated Toxicities

   Primary completion pushed from Aug 1, 2026 to Aug 1, 2027

   Also in this update: Study completion pushed from Aug 1, 2027 to Aug 1, 2028; Interventions modified

   Marcela V. Maus, M.D.,Ph.D.·Phase 2· NCT06550141· Registry history of NCT06550141 on ClinicalTrials.gov (opens the registry)

   Oct 6, 2026

2. Notable

   CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

   Primary completion pushed from Jan 1, 2027 to Aug 1, 2027

   Also in this update: Study completion pushed from Jan 1, 2028 to Aug 1, 2028

   Marcela V. Maus, M.D.,Ph.D.·Phase 1· NCT06026319· Registry history of NCT06026319 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.